Cell and Gene Therapy Commercialization: Mastering the patient-centric process

White Paper

Patients are at the very heart of the cell and gene therapy value chain. While many pharma supply chains may be considered “patient-centric,” with cell and gene therapies the patient is literally part of the supply chain because their cells or tissues are used to create the therapy. 


Mastery of the cell and gene therapy supply chain starts with a clear understanding of the patient and product journey and how they diverge from processes companies have established to support other modalities. Download the whitepaper to learn more.